Star Health & Allied Insurance Company Ltd Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
N/A
Order
Yes
Capex
N/A
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Star Health expects to grow faster than the health insurance industry, particularly in retail health.
- April 2023 premium growth is promising, with over 25% growth expected for the month.
- For FY2024, value growth is expected around 55%-60%, and volume growth around 40%-45%.
- The company aims to improve average sum assured and target more affluent customer segments.
- Market share in retail health is targeted to increase beyond FY2023 levels (currently at 34%).
- Digital initiatives and partnerships with banks and corporate agents are expected to drive growth.
- Agency strength is growing, with addition of exclusive agents aiming to double from last year’s ~18,000.
- Inclusive growth across retail and group business with focus on profitable SME groups.
- Continued focus on innovative and specialized health insurance products to drive growth momentum.
See what Star Health & Allied Insurance Company Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is a mention of new ESOP issuances planned, but these will be issued at market price and will not impact the profit and loss account significantly. (Page 6)
- No explicit statement or indication of any current or future fundraising through debt or equity is provided in the transcript.
- The company highlights a strong solvency ratio of 2.14 times, indicating a comfortable capital position without expressing any immediate need for raising capital. (Page 6 and 11)
- Discussion around profitability and capital adequacy suggests the company is well-positioned financially, with plans to maintain healthy solvency and potentially pay dividends in the future after risk-based solvency implementation. (Page 11)
- No announcements or indications regarding fresh equity or debt fundraises were made during the call.
See what Star Health & Allied Insurance Company Ltd management said on order book — free account, 30 seconds.
Capex plans
- The transcript does not explicitly mention any specific current or future capex or capital investment plans.
- It highlights ongoing strategic initiatives such as increasing exclusive agent numbers and expanding partnerships with large NBFCs.
- There is focus on improving fraud control, negotiating hospital rates, and growing profitable business segments including retail and group insurance.
- Investment strategy includes increasing exposure to ETFs from 4.1% to about 7% of the portfolio.
- No direct mention of new technology capex; however, collaboration with a fintech firm on wellness programs integrating IoT devices into their app indicates a digital/technology focus.
- ESOP issuances are planned at market price, which will not impact P&L.
- Overall, emphasis is on profitable growth and operational efficiency rather than large capex or new strategic investment announcements in this transcript.
Track Star Health & Allied Insurance Company Ltd — get its next earnings analysis in your feed
Margin guidance
Category 2- Company expects to sustain faster than industry growth in retail health segment, with promising early FY2024 performance (April growth over 25%).
- Combined operating ratio is expected to improve for FY2024, aided by price hikes, efficiency improvements, and technology-driven initiatives.
- ROE guidance for FY2024 is targeted at 16%-18%, up from 12.4% in FY2023 (adjusted for ESOP costs).
- Profit after tax for FY2023 was Rs. 619 crore (Rs. 768 crore excluding non-business costs); Q4 FY2023 PAT was Rs. 102 crore.
- APAT growth is expected from continued premium hikes and profitable product mix shifts.
- New product launches and expanded bancassurance tie-ups are expected to drive growth.
- Price increases are ongoing, monitored by product loss ratios, to maintain profitability.
- Growth strategies focus on profitable segments, including SME groups and higher sum assured products, supporting sustainable earnings expansion.
Order book
YesHow does Star Health & Allied Insurance Company Ltd rank vs peers in Insurance?
Pro featureHow does Star Health & Allied Insurance Company Ltd rank in Insurance?
Compare Star Health & Allied Insurance Company Ltd against every Insurance company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Star Health Insu's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Insurance this season
- Niva Bupa Health (Q2 FY26)
October saw over 50% growth in retail sales, driven by GST reduction from 18% to 0%, enhancing affordability and demand. Key concall takeaways from Niva Bupa…
- Medi Assist Ser. (Q3 FY26)
Expansion of technology-led revenue streams, especially from SaaS products like MAtrix and AI-driven solutions such as MAven Guard, with tech revenues growing…
- Niva Bupa Health (Q1 FY27)
Group portfolio growth remains selective, focusing on profitable segments like SMEs growing over 50% (Page 6). Key concall takeaways from Niva Bupa Health…
- HDFC Life Insur. (Q1 FY27)
Agency channel growing strongly at around 21%, driven by new agents and branch expansion. Key concall takeaways from HDFC Life Insur.'s Q1 FY27 earnings call…